High Body Mass Index and Severity of Coronavirus

High Body Mass Index and Severity of Coronavirus Disease 2019 (Covid-19): a Cohort Study

A cohort study included 114 adult patients with confirmed COVID-19 were categorized by BMI levels on admission: overweight (25-29.9 kg/m2), and obesity (four categories: 30-34.9 kg/m2, 35-39.9 kg/m2, 40-44.9 kg/m2, and ≥45 kg/m2).

Study Overview

• Status: Completed
• Conditions: COVID-19 Pneumonia
• Intervention / Treatment: Other: prospective cohort in high body mass index patient with covid 19

• Study Type: Observational
• Enrollment (Actual): 114

Contacts and Locations

Study Locations

• Egypt
  • Qena
    • Qinā, Qena, Egypt, 83511
      • Gad sayed Gad

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

114 adult patients with confirmed COVID-19 were categorized by BMI levels on admission: overweight (25-29.9 kg/m2), and obesity (four categories: 30-34.9 kg/m2, 35-39.9 kg/m2, 40-44.9 kg/m2, and ≥45 kg/m2). Pneumonia, severe pneumonia, and ICU admission rate were our primary outcomes, complications, and length of hospital stay was the secondary outcome.

Description

Inclusion Criteria:

• patients older than 18 years
• confirmed COVUID 19 infection
• body mass index more than 25kg/m2

Exclusion Criteria:

-

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
pneumonia	patients percentages	30 days
sever pneumonia	patients percentages	30 days
ICU admission	patients percentages	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
length of hospital stay	days	30 days
clinical complication	patients percentages	30 days

Collaborators and Investigators

• Sponsor: South Valley University
• Investigators: Principal Investigator: Gad S Gad, phd, ass prof ,anesthesia and ICU ,south valley university,Qena .Egypt

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2020
• Primary Completion (Actual): January 30, 2021
• Study Completion (Actual): February 28, 2021

Study Registration Dates

• First Submitted: May 3, 2021
• First Submitted That Met QC Criteria: May 3, 2021
• First Posted (Actual): May 7, 2021

Study Record Updates

• Last Update Posted (Actual): May 7, 2021
• Last Update Submitted That Met QC Criteria: May 3, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: BMI_COVID19

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No